-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

Benzinga·05/11/2026 14:00:38
Listen to the news
Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and raises the price target from $10 to $40.